Moderated Poster

Poster, Podium & Video Sessions

MP86-06: Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma

Monday, May 15
3:30 PM - 5:30 PM
Location: BCEC: Room 156

Presentation Authors: Shingo Hatakeyama*, Takuma Narita, Ken Fukushi, Shogo Hosogoe, Ayumu Kusaka, Itsuto Hamano, Hayato Yamamoto, Yasuhiro Hashimoto, Takahiro Yoneyama, Takuya Koie, Chikara Ohyama, Hirosaki, Japan

Introduction: Although quality of life (QOL) is one of the most important considerations in patients treated with anticancer therapies, desirable regimens for neoadjuvant chemotherapy including QOL in locally advanced urothelial carcinoma remain unclear. The present study evaluated the influence of neoadjuvant platinum-based chemotherapy on QOL in patients with locally advanced urothelial carcinoma.

Methods: Between June 2013 and March 2016, 83 urothelial carcinoma patients who received two courses of neoadjuvant chemotherapy were enrolled in this prospective observational study. Neoadjuvant regimens included gemcitabine+cisplatin (GCis) or gemcitabine+carboplatin (GCb) therapies. As a primary endpoint, we assessed QOL changes in each group before and after chemotherapy using the QLQ questionnaire on days 1, 3, and 15 of each cycle. Secondary endpoints included toxicity, safety, weight loss, renal function decline, and tumor responses.

Results: QOL analyses were performed in 39 patients receiving GCis and in 44 patients receiving GCb. The QOL items appetite loss, role functioning, nausea/vomiting, physical, and fatigue deteriorated >10% from baseline in the GCis group but not in the GCb group. Constipation worsened, whereas scores for pain and emotional items improved in both groups. Objective response rates were 38.5% and 43.2% in the GCis and GCb groups, respectively.

Conclusions: Both GCis and GCb regimens were feasible in terms of QOL. The GCb regimen may be associated with a better QOL status especially in regard to gastrointestinal symptoms.

Source Of Funding: none

Shingo Hatakeyama

Hirosaki University Graduate School of Medicine

SHINGO HATAKEYAMA, M.D.
Assistant Professor, Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki , JAPAN
Research interests: general urology, urological surgery, urothelial cancer, urological oncology, renal transplantation, urinary stone disease, end-stage renal disease, basic research, glycobiology

Grants
Research Project Number: 23791737, 23791740, 24659708, 17K11119. Japan Society for the Promotion of Science
The 4th Young Research Grant, 2011. Japanese Urological Association

Honors
AKITA Medical Award (2004)
Hirosaki University Hospital incentive award for Clinical skills (2006)
JUA Best Poster Award (2005, 2009, 2011, 2011)
EAU best poster Awards (2014, 2017)
JUA Award (2015)

Peer-Reviewed Journal Articles
1. Hatakeyama S., Ohyama C., Minagawa S., et al. Cancer Res. 2004 June. 64: 4257-4262.
2. Hatakeyama S, Sugihara K, Lee SH, et al. Enhancement of human sperm motility by trophinin binding peptide J Urol. 2008 Aug;180(2):767-71.
3. Hatakeyama S, Sugihara K, Nakayama J , et al. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3095-100.
4. Lee SH, Hatakeyama S, Yu SY, et al. . J Biol Chem. 2009 Apr 24.
5. Bao X, Kobayashi M, Hatakeyama Set al. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12109-14.
6. Bao X, Moseman EA, Saito H, Hatakeyama S, et al. Immunity. 2010 Nov 24;33(5):817-29.
7. Tsuboi S, Sutoh M, Hatakeyama S, et al. . EMBO J 2011 Jun 28;30(15):3173-85.
8. Hatakeyama S, Sugihara K, Shibata TK, et al. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19587-92.





Presentation(s):

Send Email for Shingo Hatakeyama


Assets

MP86-06: Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma



Attendees who have favorited this

Send Email for Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma